摘要
目的研究吉西他滨临床治疗中国老年非小细胞肺癌(NSCLC)患者的药动学特性。方法选择6例病人,固定剂量1 200 mg·m-2,0.5 h静脉输注结合铂尔锭联合给药方案。采用离子对反相高效液相色谱法测定血药浓度,用3P97计算药动学参数。结果吉西他滨的主要药动学参数:t1/2为(14.75±5.45)min;AUC0-t为(13.29±4.85)mg·h·L-1;CL为(2 797.13±837.9)mL·min-1;ρmax为(26.79±10.06)mg·L-1。结论临床使用时须注意其血液学毒性,并根据老年NSCLC患者的药动学特性适当调整剂量。
Abstract
OBJECTIVE To determine the pharmacokinetics of gemcitabine(2′,2′-difluorodeoxycytidine) in the Chinese patients with non-small-cell lung cancer(NSCLC).METHODS 6 Subjects were administered with gemcitabine at a fixed dose of 1 200 mg·m-2 for 30 min infusion.Plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography.The 3P97 Pharmaceutical kinetic software was used for the calculation of pharmacokinetic parameters.RESULTS The mean parameters were as follows: t1/2(14.75±5.45)min,AUC0-t(13.29±4.85) mg·h· L-1 and CL(2 797.13±837.9)mL·min-1,ρmax(26.79±10.06) mg·L-1.CONCLUSION With the result of hematologic toxicology,the dose should be adjusted properly in NSCLC patients.
关键词
吉西他滨 /
非小细胞肺癌 /
高效液相色谱法 /
药动学
{{custom_keyword}} /
Key words
gemcitabine /
non-small-cell lung cancer /
high performance liquid chromatography /
pharmacokinetics
{{custom_keyword}} /
黄明珠;王临润;蔡捷;申屠建中.
吉西他滨在中国老年非小细胞肺癌患者体内的药动学研究[J]. 中国药学杂志, 2008, 43(23): 1819-1822
HUNG Ming-zhu;WNG Lin-run;CI Jie;SHEN-TU Jing-zhong.
Pharmacokinetics of Gemcitabine in Chinese Old Patients with Non-Small-Cell Lung Cancer [J]. Chinese Pharmaceutical Journal, 2008, 43(23): 1819-1822
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LARRY W H，GEORGE B B，STAN J，et al. Evaluation of the antitumor activity of gemcitabine [J] . Cancer Res，1990，50(14)：4417-4422.
[2] ZHU W Y，SHU Y Q. Review of progress in the treatment of non-small-cell lung cancer with gemcitabine[J] . Chin Clin Oncol(临床肿瘤学杂志)，2004，9 (1)： 94-99.
[3] SCHILLER JII. Future directions in non-small-cell lung cancer[J] . Semin Oncol，1999，26(2 suppl 7)：120-124.
[4] FOGLI S，DANESI F，BRAUD D E，et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer [J] . Ann Oncol，2001，12（11）：1553-1559.
[5] PEREZ-MANGA G，LLUCH A，ALBA E，et al. Gemcitabine in combination with doxorubicin in advanced breast cancer： final results of a phase Ⅱ pharmacokinetic trial[J] . J Clin Oncol，2000，18(13)：2545-2552.
[6] KIANI A，KOHNE C H，FRANZ T，et al. Parmacokinetics of gemcitabine in a patient with end-stage renal disease：effective clearance of its main metabolite by standard hemodialysis treatment[J] . Cancer Chemother Pharmacol, 2003，51(3)：266-270.
[7] IAFFAIOLI R V，TORTORIELLO A，GAE- TANO F，et al. PhaseⅠ-Ⅱstudy of gemcitabine and carboplatin in stage ⅢB-Ⅳ non-small-cell lung cancer[J] . J Clin Oncol，1999(3)：921-931.
[8] LICHTMAN S M，VILLANI G. Chemotherapy in the elderlysp- harmacologic considerations [J] . Cancer Control，2000，7(6)：548-556.
[9] WU H B，PAN H Q，LIU J S. The adverse reaction and preven- tion of gemcitabine[J] . Adv Drug React J（药物不良反应杂志），2003，5(3)： 176-177.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
浙江省医药卫生科技基金资助(2004A028)
{{custom_fund}}
